Prediction of efficacy for conversion from adjunctive therapy to monotherapy with eslicarbazepine acetate 800 mg once daily for partial-onset epilepsy

PURPOSE: Eslicarbazepine acetate (ESL) is a once-daily (QD) oral antiepileptic drug (AED) indicated for partial-onset seizures (POS). Clinical studies of gradual conversion to ESL 1,200 and 1,600 mg QD monotherapies were previously conducted in patients with POS who were not well-controlled by 1 or...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Clin Pharmacol
Hlavní autoři: Sunkaraneni, Soujanya, Passarell, Julie A, Ludwig, Elizabeth A, Fiedler-Kelly, Jill, Pitner, Janet K, Grinnell, Todd A, Blum, David
Médium: Artigo
Jazyk:Inglês
Vydáno: Dove Medical Press 2017
Témata:
Original Research
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5500545/
https://ncbi.nlm.nih.gov/pubmed/28721105
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/CPAA.S133815
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky